Abstract
INTRODUCTION
Wilson's disease (WD) is an autosomal recessive disorder of copper (Cu) metabolism, resulting from defects in the ATP7B gene protein. It is characterized by failure of Cu incorporation into ceruloplasmin (Cp) and decreased biliary Cu excretion. As a con sequence, Cu accumulates in various organs, primarily liver and brain. The clinical presentations of WD are characterized by substantial diversity. Patients can present at any age in variable combinations of liver impairment, neurologic dysfunction and/or osseomuscular symptom. Hepatic manifestations include asymptomatic transaminitis, acute or chronic hepatitis, fulminant hepatic failure and/or cirrhosis, while neurologic symptoms vary from mild tremors, articulating problems, dysarthria, Parkinsonlike features, seizures and cognitive dysfunction. Some patients have mixed hepatoneurologic presentation [1] . Ophthalmologic involvement with KaiserFleischer (KF) rings is common.
Traditionally, the diagnosis of WD is based on low serumCp (< 20 mg/dL), high 24h urinary Cu and high hepatic Cu content (250 µg/g dry tissue) [2, 3] . Recent guidelines for the diagnosis of WD were published by the European Association for the Study of the Liver (EASL) [4] . Nonetheless, the diagnosis of WD may be difficult based on clinical and laboratory criteria, and in some patients it is delayed, leading to detrimental consequences [5] . This is why molecular testing and genotypic analysis may be warranted for confirming and/or supporting a diagnosis of WD, particularly in asymptomatic patients [3] . More than 500 mutations have been identified in WD with a very high allelic heterogeneity. Most patients are compound heterozygous, rendering it difficult to ascribe a phenotype to a specific genotype [6] . Furthermore, a large number of mutations are rare, making it im practical to screen populations for all WDcausing mutations [7] . Some mutations, however, are relatively frequent and populationspecific, like the p.His1069Gln on exon 14 in Northern and Eastern European patients [8] , the p.Arg778Leu and the p.Arg778Gly mutations on exon 8 among Chinese and Taiwanese patients respectively [9] , and the deletion in the 5' regulatory region in Sardinian patients [10] . These findings facilitate molecular diagnosis based on patients' ethnic background. In the Arab World, consanguinity and marriage among individuals belonging to the same ethnic background is very common, thereby increasing the prevalence of genetic disorders, including WD [11] . However, it is not known whether there is a predominant WD mutation in the Arab world, and if so what its phenotypic associations are.
In a cohort of Egyptian patients, genotypic and phenotypic profiles were described, but no prevalent mutation was identified [12] . Moreover, previous reports from Lebanon on a limited number of families suggested an association of liver presentation with homozygous missense mutations: Gly691Arg and nonHis1069Trp in exons 7 and 14 of the ATP7B gene respectively [13, 14] . Whether a specific WD mutation prevails in Lebanon is not known.
In this study, we described the spectrum and frequency of mutations and phenotypes in 36 Lebanese WD patients. We also conducted a comprehensive literature search for regional studies on WD in Arab and nonEuropean countries in the Middle East. In order to determine whether there is a frequent mutation characterizing the region, a comparative study was undertaken to identify common mutations in the region, and to compare them to our data. We also determined if common mutations in the region were associated with similar clinical phenotypes.
MATERIALS AND METHODS
A total of 36 patients (P1P36) from 13 unrelated Le banese families (U, Or, S, Ah, T, B, H, Ha, Is, Z, Ri, Sc and Gh) were enrolled in the study. Most patients were diagnosed at the American University of Beirut (AUB) Medical Center, a major tertiary referral center in Lebanon. All participating subjects were asked to sign a written consent form (Protocol No. BioCh.JU.01) that was approved by both the Institutional Review Board and Research Committee at AUB.
Clinical testing
Patients' data for evaluation included: history, date of birth, age of onset of symptoms, age at diagnosis, and findings from full physical exam, ophthalmologic slitlamp examination, and biochemical tests, including liver function tests, serumCp and 24h urinaryCu levels. Abdominal ultrasound imaging of the liver was performed on all patients and, when necessary, brain magnetic resonance imaging was done. Phenotypic classifications were designated following Ferenci's classification as hepatic, neurologic, mixed or asym ptomatic [3] . Diagnosis was further established by computing total WD score developed at the 8 th inter national meeting [15] . Family members (siblings, parents) of all WD-confirmed index patients were also subjected to physical, biochemical and genotypic testing.
Genotypic screening
DNA screening for diseasecausing mutations and single nucleotide polymorphisms was performed on all recruited subjects and their immediate family members. Extraction of DNA from blood samples followed by amplification (using PCR) of the 21 ATP7B exons was carried out as described [6, 14] . Amplified PCR products were purified, sequenced and compared to published normal sequences in the following data banks: Blat at University of California SantaCruz, Genome Bioinformatics (http://www.Genome.ucsc. edu/cgibin/hgBlat) or Blast at National Center for Biotechnology Information (http://www.ncbi.nih.gov/ blast).
WD in regional countries
After identifying the diseasecausing mutations in our patients, we compared them to reported mutations in WD patients from regional Arab and NonEuropean countries. A comprehensive literature search of We included studies in which both the genotype and phenotype were identified. In some studies, it was not clearly indicated whether patients presenting to one medical center with a certain mutation belonged to the same family or to different ethnic groups [16, 17] . This made it difficult to estimate the most frequent genotype. We, therefore, opted to identify common mutations between Lebanon and the region, and to determine the frequent regional mutations as indicated by the authors of the various reports.
RESULTS

Clinical presentation
In this study, 36 Lebanese WD patients, including 15 females and 21 males, were recruited from different regions in Lebanon. Patients belonged to 13 unrelated families, referred to as: U (P1P9); Or (P10); S (P11P19); Ah (P20); T (P21P23); B (P24P25); H (P26P28); Ha (P29P30); Is (P31); Z (P32P33); Ri (P34); Sc (P35); and Gh (P36) families. Consanguinity was present in the parents of 27 of the patients (75%), who belonged to the U, S, B, H, Ha, and Z families (Table 1) . WD scores computed following EASL guidelines ranged between 4 and 12 ( Table 2) , confirming the diagnosis.
The clinical profiles of affected subjects are su mmarized in Table 2 . Age at diagnosis ranged between 1 and 39 years. All patients had low Cp level (< 0.2 g/L), except for P4 and P14. Out of 31 patients, 18 (58%) had KF rings (5/36 were NAV). Out of the 36 WD patients, 24 were symptomatic (67%; 16 males and 8 females) and presented clinically at an average age of 14.5 years. Data on P6P9 were not available. Twelve patients were asymptomatic (33%), diagnosed by genetic screening of family members of index patients. Their average age was 7.6 years.
Pure hepatic phenotype was the most common in our symptomatic patients [9/32: P1, P16P17, P18, P20, P25, P27P28 and P32]. Neurologic presentation was noted in 12.5% of patients (4/32: P12, P14, P34 and P36). Mixed presentation was observed in 25% of patients (7/32: P2, P10, P24, P26, P29, P31 and P35), two of whom had suicidal attempts/disposition (P10 and P26). Notably, liver cirrhosis was present in 12 symptomatic (38%) patients (P1, P2, P10, P16P18, P20, P24, P26P28 and P32), including 4 patients with mixed presentation.
Of the asymptomatic subjects who were diagnosed by screening, 10/12 patients had evidence of liver disease, ranging from transaminitis (P3P5, P11, P13, mutation(s) were detected in 51:16:3 chromosomes at 72.8%:22.8%:4.3% frequency respectively. No mutation was identified in P36, who had been diagnosed based on KF rings, and clinical and biochemical testing.
Out of 35 patients, 29 were homozygous (82.8%) for a diseasecausing mutation and 6 were compound heterozygous (17.1%). Parents of our index patients were carriers for the diseasecausing mutations. Mutations were most frequent in the exon 18 motif encoding the conserved ATP hinge region of WD gene product. Four out of the 13 unrelated families (H, Ha, Is and Z) had, in this motif, missense mutations in the homozygous state; these were Asn1270Ser in 6 patients (P26P31) and Pro1273Leu in 2 patients (P32P33), accounting for 17% and 5.7% of chromosomes respectively. Other identified mutations (Table 1) included missense mutations in exon 7 (Gly691Arg; 10 patients: U and Or) and exon 12 (Trp939Cys; 5 patients: T and B), frameshift in exon 8 (2299insC; 10 patients: S and Ah), and nonsense mutation in exon 19 (Arg1319stop; 2 patients: Ri and Sc), accounting for a chromosome frequency of 27%, 14%, 23% and P21P23, P30 and P33) and hepatomegaly detected by abdominal ultrasound (P11, P13 and P21) to full blown cirrhosis (P22P23). Overall, 27/32 patients (84%) on whom we had clinical information presented with some form of hepatic dysfunction.
Patients with the neurologic phenotype presented at an average age of 22.3 years, while those with hepatic and mixed phenotypes presented at 12.2 and 14 years, respectively. KF rings were present in 17 symptomatic patients (5 symptomatic were NAV) and absent in two (P25, P34). They were not identified in the asymptomatic patients, except for patient P19 who had KF rings with no evidence of hepatic or neurologic dysfunctions.
Mutation analysis
Sequencing of the ATP7B gene revealed (Table  1) 9 different diseasecausing mutations in 70 chromosomes (35 patients), which were distributed as: 7 missense (exons: 7, 12, 10, 13, 15 and 18), 1 non sense (exon 19) , and 1 frameshift (exon 8). Out of 70 chromosomes, missense/frameshift and/nonsense 
WD patients: Lebanon vs regional countries
A search of the literature for population studies on the spectrum of mutations in WD patients in the region, including Arab and nonEuropean countries, was conducted. A total of 77 articles on WD patients were initially identified, but only those reporting the genotypes and/or the phenotypes were considered. Consanguinity, homozygosity and frequency of mutation were also noted when indicated. Seventeen articles were included and distributed as follows: Saudi Arabia [1821] , Egypt [12, 2224] , Turkey [25, 26] , Iran [27, 28] , Oman [29] and Lebanon [6, 13, 14, 30] . Two reports on WD from Iraq were not included, as they had no genotypic information. There were no reports on WD from Jordan, Libya, Tunisia, Morocco or Syria.
Homozygosity was highly prevalent in Lebanese WD patients (83%), and ranged between 68%85.7% and 50%53% in Egyptian and Saudi Arabian patients respectively. This finding is attributed to high consanguinity ( Table 4 ) that is common in our societies, or the high prevalence of the same mutation in carriers. Frequency of asymptomatic cases was relatively similar in Lebanon, Egypt and Saudi Arabia. Similar to Lebanese patients, many of asymptomatic patients had evidence of hepatic dysfunction on laboratory and/or imaging studies. Hepatic phenotype was more common than neurologic phenotype in patients from Lebanon, Egypt, Turkey, Iran and Saudi Arabia. Taking into account patients who are asymptomatic and those with mixed phenotype, the vast majority of patients in those countries have some form of hepatic dysfunction. A minority of patients had pure neurologic phenotype. Also, the frequency of patients having KF rings was high and was similar in the 5 countries (Table 4 ). In a report on a single family from Oman, 78% of patients were asymptomatic and 21% had neurologic phenotype. No patients had a hepatic phenotype in that study.
In conducting our analysis of genotypes, we con sidered a mutation to be frequent if it was present in multiple unrelated families. We compared genotypic changes in the ATP7B gene of Lebanese patients with those from regional Arab and nonEuropean patients. In our patients, the conserved ATP hinge region (exon 18) was the most frequently mutated region identified in 4 unrelated families (Table 1) . Table 3 shows that Lebanese patients share in common with: (1) Egypt, Iran and Turkey, the Val845Ser and Asp1270Ser mutations in exons 10 and 18 respectively; (2) Egypt, the Pro1273Leu mutation in exon 18; (3) Egypt and Turkey, the Arg1319X mutation in exon 19; and (4) Turkey, the Ala1003Thr mutation in exon 13 and the exon 7 mutation (Gly691Arg) reported in one Turkish patient [26] . More interestingly, the mutation in exon 12 (Trp939Cys) was only detected in Lebanese patients and in none of the searched/ listed countries. Whereas the worldwide exon 14 mutation (His1069Gln) was detected in some patients from Egypt, Iran and Turkey, it was not identified in Lebanese or in Saudi Arabian patients.
DISCUSSION
The diagnosis of WD based on clinical grounds alone is often difficult. Thus, it may be necessary to resort to genetic testing. In this study, involving more than 500 patients from Lebanon and the region, we found a great deal of genetic heterogeneity with no common or population specific mutation. This reflects the extensive ethnic diversity of people in this part of the world and argues against the presence of a founder gene, even in highly consanguineous populations. It also implies that patients suspected to have WD without a family history, i.e., without a known mutation in their family, may need to be screened for mutations in all exons of the ATP7B gene. In view of clustering of WD patients within families, their members should be screened for mutations identified in index patients. This is important as it could prevent the silent progression of WD, which may occur as early as 1 year of age, and facilitate management. Based on the recently published EASL criteria for diagnosis, all our symptomatic and asymptomatic patients had a composite score > 4 (range: 6-12), confirming 
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No common mutations identified Ref.
Barada et al [13, 30] Abdelghaffar et al [12, 22] Dastsooz et al [27] Simsek Papur et al [25] Al Jumah et al [18] Al-Tobi et al [29] Al Fadda et al [19] Usta et al [6, 14] El-Karaksy et al [23] Zali et al [28] Loudianos et al [26] Majumdar et al [20, 21] El-Mougy et al [24] 1 152 patients described in articles from Saudi Arabia, of which 5 patients were from yemen and syria.
the diagnosis beyond doubt. In many of our patients, confirmation of the diagnosis required mutation analysis. Traditionally WD was diagnosed on the basis of low Cp level, KF ring presence and increased 24h urine Cu level in the context of hepatic and/or neurologic manifestations [31] . In our experience, many patients with WD do not satisfy all these criteria. For example, patients P4 and P14 had normal Cp, 13 did not have KF rings and 4 had normal 24h urinary Cu. This highlights the difficulties and challenges of making a diagnosis of WD based on clinical grounds alone, particularly in asymptomatic patients.
Worldwide, the majority of WD patients are com pound heterozygous [32] . In contrast, in our community, the high rate of consanguinity increases the chance of homozygosity, which is present in 83% of our patients. Only 17% of our patients were compound heterozygous. Missense mutations were the most predominant in Lebanese patients, as worldwide [33] . These occurred in 8 exons of ATP7B. One possible hot spot of the WD gene in our patients is that of the conserved ATP hinge region in exon 18. Two mutations in the homozygous state, Pro1273Leu and Asn1270Ser, were the most frequent, being identified in 8 patients from 4 unrelated families. None of the possible hot spot mutations in Lebanon were shared with those of Asia, Latin America or Europe.
One of our WD patients had no identifiable mutations in the coding region of the ATP7B gene. Mutations may be present in the promoter or the transcription factor regions which control protein translation and function. In such cases, detailed clinical testing and family history may be of help in diagnosis, such as P36, in whom the diagnosis was based on clinical assessment showing low Cp and presence of KF rings in the context of neurologic manifestation. Finally, all our patients had multiple genetic polymorphisms that may influence the final folded conformation, affinity and/or the function of the Wilson protein and possibly the phenotype of WD patients [34] . Remarkable differences in phenotypes and age at diagnosis were noted among patients and even among family members carrying the same genotype. The age of onset of the disease varied between 122 years, with one (P36) diagnosed at 39 years. In the B family, patient P25 was diagnosed at 5 and passed away before the onset of his brother's symptoms at the age of 13 (P24). Variation in age at diagnosis was also observed in asymptomatic cases. During a checkup at the age of 7, the female index patient in family T (P21) was found to have transaminitis and hepatomegaly. She was confirmed to have WD and was homozygous for a mutation in exon 12. Genetic screening of her 2 brothers, P22 (8 years) and P23 (3 years), confirmed WD. Though they were asymptomatic, it was sur prising to find that both already had evidence of liver cirrhosis on liver imaging. This raises the question as to whether sex plays a role in the clinical manifestations of disease [15] . Verification of this, however, requires a cohort study with a larger number of patients. Such phenotypic diversity has been reported even among monozygotic twins [35] , suggesting a role for epigenetic and/or environmental factors in the expression of WD [3638] . Diversity in clinical presentation introduces yet another obstacle in the diagnosis of WD, regardless of whether the patient is symptomatic or asymptomatic. A patient, at age of diagnosis, may have mild to severe hepatic and/or neurologic symptoms with or without KF rings. This emphasizes, again, the limitations of pure clinical evaluation and argues for genetic testing of all family members of an affected sibling. In our patients, 28% had pure hepatic manifestations ranging from transaminitis and hepatomegaly to clinically unapparent or overt cirrhosis and portal hypertension. On the other hand, only 9% of our patients had pure neurologic symptoms ranging from weak school per formance, slurred speech, tremors, drooling, dysarthria, dysphagia and ataxia to suicidal attempts in some (P10 and P26).
Our asymptomatic patients (36%) were found to have liver involvement (transaminitis, fatty liver and cirrhosis) with no KF rings, except for P19. Changes such as fatty liver were detected at the age of 1 year in P15, diagnosed by genetic screening. Therefore, early diagnosis is important in families with index patient(s), to mitigate against progression of the disease. This is in line with the EASL recommendations to perform genetic testing for WD, in individuals with liver disease or neurologic movement disorders of unclear etiology. Whether genetic testing for WD in patients with unexplained hepatic dysfunction will turn out to be cost effective or not in this part of the world is unclear.
Few studies from the Arab world on WD from Lebanon, Egypt, Saudi Arabia and Oman have been published. Similar to Lebanon, the majority of patients from Egypt and Saudi Arabia have consistently shown a high prevalence of consanguinity and homozygosity, with a great deal of genetic heterogeneity, and no mutation characteristic of the region identified. The predominant phenotype of WD in the region was also hepatic, suggesting the benefits of screening for WD in patients with unexplained hepatic dysfunction.
Lebanese and Egyptian patients share missense mutations in exons 8, 10, 18 and 19 (Table 4) . How ever, mutations Gly691Arg and Trp939Cys were identified in Lebanese patients but not in Saudi Arabian or Egyptian ones. There were also common mutations with Turkish WD patients, including exon 7 (Gly691Arg), exon 10 (Val845Ser), exon 13 (Ala1003Thr), exon 18 (Asp1270Ser) and exon 19 (Arg1319stop). Only exon 10 (Val845Ser), and exon 18 (Asp1270Ser) were shared with Iranian patients. Interestingly, the exon 12 mutation of Trp939Cys was detected in Lebanon but not in any regional country. We reported this mutation in the homozygous state in 5 Lebanese patients, while worldwide it was only detected in 1 Hungarian patient in the heterozygous state [39] . This extensive genotypic diversity argues for testing patients suspected to have WD for mutations in all exons of ATP7B. The shared mutations with the region may be attributed to common ancestors (Turkey and Egypt) who ruled Lebanon in the past. The origin of the Trp939Cys mutation, however, remains undetermined.
To our surprise, the His1069Gln mutation which is common in diverse populations in North America, Europe and several Mediterranean countries [40] was not present in Lebanese patients, but was reported in a minority of patients from Egypt, Iran and Turkey. We did not identify a predominant mutation in Lebanon or the region. Whether mutations in the ATP hinge region in exon 18 may turn out to be a hot spot in this part of the world requires further studies on larger numbers of WD patients. One major strength of our study is that it involves more than 500 patients from Lebanon and the region. It includes a comprehensive clinical and genetic assessment of WD patients in Lebanon, as well as studies from the region clearly stating the genotype and phenotype. Our patients belonged to extended consanguineous families having similar environmental exposures and dietary habits, which helped in reducing the effects of compounding factors on the genotype and phenotype of patients. In addition, our study has some limitations including the absence of true population studies and the lack of longterm followup to determine reliably the true phenotype of patients. It is possible that many WD patients in Lebanon and the region remain undiagnosed or unreported, hence missing new mutations and other genotypephenotype associations.
In conclusion, WD in Lebanon and the region is characterized by extensive genotypic and phenotypic diversity, and by high rates of consanguinity and homozygosity. No predominant mutation has been identified in the region, while the predominant phe notype seems to be hepatic. Clinical and/or genetic testing of all family members for WD, as well as those with unexplained hepatic dysfunction may increase the detection rate of the disease. This could facilitate early institution of therapy and reduce the mortality and morbidity of this condition.
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COMMENTS
Background
Wilson's disease (WD) is an autosomal recessive disorder of copper metabolism, characterized by extensive phenotypic diversity. Most of the patients are compound heterozygotes, having different mutation on each of the ATP7B alleles. Attempts to establish genotype-phenotype correlations was hampered by the large number of mutations in the ATP7B gene and difficulty in ascribing a phenotype to one allele. This, however, may be overcome by examining WD in homozygous patients. In Lebanon, consanguinity is quite prevalent, increasing the probability of homozygosity and possibility of establishing a phenotype-genotype correlation. They hereby report the spectrum of mutations and phenotypes of 36 Lebanese patients diagnosed with WD. In addition, we examine if a frequent mutation characterizing the region exists by comparing our findings with those reported from regional studies on WD in Arab and non-European countries.
Research frontiers
This manuscript examines whether genotype-phenotype correlation exists in Lebanese patients diagnosed with WD. It also determines if a frequent mutation characteristic of the Lebanese patients and/or the region occurs.
Innovations and breakthroughs
This is the first comparative study that attempts to identify a frequent mutation characterizing WD patients from Lebanon and regional Arab and non-European countries. Although this region is characterized by high rates of consanguinity and homozygosity, no frequent mutation has been identified in the region but predominance of the hepatic phenotype was noted.
Applications
This study improves our understanding of WD pathogenesis and the genetic determinants of patients' phenotype. It emphasizes the importance of genetic screening for WD in family members with index patients, as well in patients with unexplained hepatic dysfunction. This would surely facilitate diagnosis and early management prior to onset of symptoms, thereby preventing the progressive clinical deterioration of the patient.
Terminology
WD is a rare disease of copper homeostasis that results from a defect in the ATP7B gene encoding a copper transporter. Ceruloplasmin is the major copper carrying protein in blood with ferroxidase activity. Kaiser-Fleischer rings refer to copper deposition circumscribing the iris of the eye, diagnostic of WD.
